SCHEMBL1337019

SCHEMBL1337019

Nc1c(F)cc(-c2ccc3c(c2)OCO3)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.44
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
PTGS2 P35354 3/20 0.44
PTGS1 P23219 2/20 0.44
PLG P00747 1/20 0.42
PLAU P00749 1/20 0.42
KIF11 P52732 1/20 0.41
ALDH1A1 P00352 4/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 2/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 2/20 0.41
NFKB1 P19838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337772 0.91 ALOX5 (0.45) PTGS2PTGS1ALDH1A1NPC1RAB9A
SCHEMBL1337704 0.89 CA12 (0.50) SRCCA12CA2CA9PTGS2
SCHEMBL3903052 0.79 CA12 (0.50) SRCCA12CA2CA9PTGS2
SCHEMBL1337590 0.78 DYRK1A (0.57) PLAUNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL22162812 0.74 CA12 (0.58) SRCCA12CA2CA9PTGS2
SCHEMBL27765776 0.71 CNR1 (0.56) SRCCA12CA2CA9PTGS2
SCHEMBL14451001 0.71 CA12 (0.56) SRCCA12CA2CA9PTGS2
SCHEMBL3901839 0.71 CA12 (0.61) SRCCA12CA2CA9PTGS2
SCHEMBL5952330 0.70 KMT2A (0.56) SRCCA12CA2CA9PTGS2
SCHEMBL3822936 0.70 CA1 (0.43) CA2CA9PTGS2PTGS1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR SRC 4626/4885CA12 2965/4885CA2 1430/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR SRC 4626/4885CA12 2965/4885CA2 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.